Form 3: 6,900,000 LIMN Shares Disclosed by Iris Acquisition Holdings

Rhea-AI Filing Summary

Liminatus Pharma, Inc. (LIMN) Form 3 shows an initial statement of beneficial ownership filed for Iris Acquisition Holdings LLC in connection with an event dated 04/30/2025. The reporting entity lists a total of 6,900,000 shares of Common Stock beneficially owned in a direct ownership form. The filing identifies the reporting person as related to the issuer with the label string that includes Director. The document is signed by Sumit Mehta, Authorized Representative with a signature date of 08/15/2025. No derivative securities are reported and no exercise or conversion terms are listed.

Positive

• Clear initial disclosure of beneficial ownership satisfying Section 16 reporting for the 6,900,000-share position
• No derivative securities reported, indicating the position is solely common stock with no attached options or warrants disclosed

Negative

• None.

Insights

Securities Analyst

TL;DR: Initial disclosure of a sizable direct stake of 6.9M shares in LIMN, reported on Form 3; no derivatives disclosed.

The Form 3 documents an initial beneficial ownership filing for Iris Acquisition Holdings LLC reporting 6,900,000 shares of common stock as directly owned. The filing records an event date of 04/30/2025 and a signature by an authorized representative on 08/15/2025. There are no derivative positions reported, so the stake is purely equity with no listed options, warrants, or convertibles attached in this filing. From an investor-disclosure perspective, this meets Section 16 initial reporting requirements by identifying a principal holder and the size of the position.

Corporate Governance Expert

TL;DR: Form 3 notifies the market of a new direct stake; governance implications depend on context not provided here.

The filing names Iris Acquisition Holdings LLC and contains the relationship string that includes Director, indicating a governance linkage noted on the form. The report does not provide additional governance details, such as whether the holder will join the board or any agreements tied to the shares. Absent further disclosures or amendments, this Form 3 serves as a baseline ownership disclosure without additional governance commitments or restrictions described.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Iris Acquisition Holdings LLC

(Last) (First) (Middle)

3RD FLOOR ZEPHYR HOUSE

122 MARY STREET, P.O. BOX 10085

(Street)

GEORGE TOWN E9 KY1-1001

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/30/2025

3. Issuer Name and Ticker or Trading Symbol
Liminatus Pharma, Inc. [ LIMN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	6,900,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Sumit Mehta, Authorized Representative	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stake did Iris Acquisition Holdings LLC disclose in Liminatus Pharma (LIMN)?

The filing discloses 6,900,000 shares of Common Stock beneficially owned in a direct form.

When is the event date and when was the Form 3 signed for LIMN?

The event date listed is 04/30/2025 and the form is signed by an authorized representative on 08/15/2025.

Does the Form 3 report any derivative securities for LIMN?

No. The Form 3 lists no derivative securities and provides no exercisable or convertible instruments.

Who signed the Form 3 filing for Iris Acquisition Holdings LLC?

The filing is signed by Sumit Mehta, Authorized Representative.

Does the Form 3 indicate any governance role for the reporting person at LIMN?

The relationship line in the filing includes the label string with Director, but the form provides no further governance details.